CD8A and chronic obstructive pulmonary disease: Interestingly, ICS discontinuation in COPD patients results in increased bronchial CD3+, CD4+, and CD8+, along with increased sputum total cell counts (Kunz et al., 2017), further demonstrating the local anti-inflammatory effect of ICS.